368 related articles for article (PubMed ID: 21868756)
1. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer.
Pan D; Kocherginsky M; Conzen SD
Cancer Res; 2011 Oct; 71(20):6360-70. PubMed ID: 21868756
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.
West DC; Kocherginsky M; Tonsing-Carter EY; Dolcen DN; Hosfield DJ; Lastra RR; Sinnwell JP; Thompson KJ; Bowie KR; Harkless RV; Skor MN; Pierce CF; Styke SC; Kim CR; de Wet L; Greene GL; Boughey JC; Goetz MP; Kalari KR; Wang L; Fleming GF; Györffy B; Conzen SD
Clin Cancer Res; 2018 Jul; 24(14):3433-3446. PubMed ID: 29636357
[No Abstract] [Full Text] [Related]
3. Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association.
Tonsing-Carter E; Hernandez KM; Kim CR; Harkless RV; Oh A; Bowie KR; West-Szymanski DC; Betancourt-Ponce MA; Green BD; Lastra RR; Fleming GF; Chandarlapaty S; Conzen SD
Breast Cancer Res; 2019 Jul; 21(1):82. PubMed ID: 31340854
[TBL] [Abstract][Full Text] [Related]
4. GR and ER Coactivation Alters the Expression of Differentiation Genes and Associates with Improved ER+ Breast Cancer Outcome.
West DC; Pan D; Tonsing-Carter EY; Hernandez KM; Pierce CF; Styke SC; Bowie KR; Garcia TI; Kocherginsky M; Conzen SD
Mol Cancer Res; 2016 Aug; 14(8):707-19. PubMed ID: 27141101
[TBL] [Abstract][Full Text] [Related]
5. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR
Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor, progesterone receptor, and glucocorticoid receptor expression in normal breast tissue, breast in situ carcinoma, and invasive breast cancer.
Buxant F; Engohan-Aloghe C; Noël JC
Appl Immunohistochem Mol Morphol; 2010 May; 18(3):254-7. PubMed ID: 19875955
[TBL] [Abstract][Full Text] [Related]
7. Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.
Prekovic S; Chalkiadakis T; Roest M; Roden D; Lutz C; Schuurman K; Opdam M; Hoekman L; Abbott N; Tesselaar T; Wajahat M; Dwyer AR; Mayayo-Peralta I; Gomez G; Altelaar M; Beijersbergen R; Győrffy B; Young L; Linn S; Jonkers J; Tilley W; Hickey T; Vareslija D; Swarbrick A; Zwart W
EMBO Mol Med; 2023 Dec; 15(12):e17737. PubMed ID: 37902007
[TBL] [Abstract][Full Text] [Related]
8. Hormone receptors in breast cancer: more than estrogen receptors.
Lamb CA; Vanzulli SI; Lanari C
Medicina (B Aires); 2019; 79(Spec 6/1):540-545. PubMed ID: 31864223
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup.
Alles MC; Gardiner-Garden M; Nott DJ; Wang Y; Foekens JA; Sutherland RL; Musgrove EA; Ormandy CJ
PLoS One; 2009; 4(3):e4710. PubMed ID: 19270750
[TBL] [Abstract][Full Text] [Related]
10. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.
Skor MN; Wonder EL; Kocherginsky M; Goyal A; Hall BA; Cai Y; Conzen SD
Clin Cancer Res; 2013 Nov; 19(22):6163-72. PubMed ID: 24016618
[TBL] [Abstract][Full Text] [Related]
11. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
[TBL] [Abstract][Full Text] [Related]
12. Contribution of Immune Cells to Glucocorticoid Receptor Expression in Breast Cancer.
Gandhi S; Elkhanany A; Oshi M; Dai T; Opyrchal M; Mohammadpour H; Repasky EA; Takabe K
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32629782
[TBL] [Abstract][Full Text] [Related]
13. Glucocorticoid receptor-IRS-1 axis controls EMT and the metastasis of breast cancers.
Shi W; Wang D; Yuan X; Liu Y; Guo X; Li J; Song J
J Mol Cell Biol; 2019 Dec; 11(12):1042-1055. PubMed ID: 30726932
[TBL] [Abstract][Full Text] [Related]
14. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.
Iwamoto T; Bianchini G; Booser D; Qi Y; Coutant C; Shiang CY; Santarpia L; Matsuoka J; Hortobagyi GN; Symmans WF; Holmes FA; O'Shaughnessy J; Hellerstedt B; Pippen J; Andre F; Simon R; Pusztai L
J Natl Cancer Inst; 2011 Feb; 103(3):264-72. PubMed ID: 21191116
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
16. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
[TBL] [Abstract][Full Text] [Related]
17. ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer.
Madhavan S; Gusev Y; Singh S; Riggins RB
J Exp Clin Cancer Res; 2015 May; 34(1):45. PubMed ID: 25971350
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression.
Kinyamu HK; Archer TK
Mol Cell Biol; 2003 Aug; 23(16):5867-81. PubMed ID: 12897156
[TBL] [Abstract][Full Text] [Related]
19. High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes.
Riaz M; Sieuwerts AM; Look MP; Timmermans MA; Smid M; Foekens JA; Martens JW
Breast Cancer Res; 2012 Sep; 14(5):R123. PubMed ID: 22967435
[TBL] [Abstract][Full Text] [Related]
20. EPRS is a critical regulator of cell proliferation and estrogen signaling in ER+ breast cancer.
Katsyv I; Wang M; Song WM; Zhou X; Zhao Y; Park S; Zhu J; Zhang B; Irie HY
Oncotarget; 2016 Oct; 7(43):69592-69605. PubMed ID: 27612429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
